MADDEN SECURITIES Corp Grows Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

MADDEN SECURITIES Corp grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 19.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,081 shares of the medical research company’s stock after buying an additional 3,140 shares during the period. Charles River Laboratories International accounts for 2.2% of MADDEN SECURITIES Corp’s portfolio, making the stock its 13th biggest position. MADDEN SECURITIES Corp’s holdings in Charles River Laboratories International were worth $4,158,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Ronald Blue Trust Inc. purchased a new stake in Charles River Laboratories International in the second quarter worth about $25,000. Pinnacle Financial Partners Inc. bought a new stake in shares of Charles River Laboratories International during the third quarter valued at approximately $26,000. Trustcore Financial Services LLC boosted its position in shares of Charles River Laboratories International by 72.0% during the third quarter. Trustcore Financial Services LLC now owns 172 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 72 shares in the last quarter. SRS Capital Advisors Inc. purchased a new stake in Charles River Laboratories International in the second quarter worth $35,000. Finally, Huntington National Bank lifted its position in Charles River Laboratories International by 53.7% during the third quarter. Huntington National Bank now owns 189 shares of the medical research company’s stock valued at $37,000 after buying an additional 66 shares during the period. Institutional investors own 97.80% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CRL. Credit Suisse Group reduced their target price on shares of Charles River Laboratories International from $280.00 to $260.00 and set an “outperform” rating on the stock in a research report on Thursday, February 23rd. StockNews.com initiated coverage on shares of Charles River Laboratories International in a report on Thursday. They set a “hold” rating for the company. Robert W. Baird boosted their price target on Charles River Laboratories International from $275.00 to $285.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 11th. Morgan Stanley reduced their price objective on Charles River Laboratories International from $241.00 to $230.00 and set an “equal weight” rating for the company in a research report on Thursday, February 23rd. Finally, Citigroup decreased their target price on Charles River Laboratories International from $280.00 to $260.00 and set a “buy” rating for the company in a research report on Thursday, February 23rd. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $270.83.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded down $0.64 during midday trading on Friday, hitting $192.92. The company had a trading volume of 1,096,553 shares, compared to its average volume of 588,236. Charles River Laboratories International, Inc. has a 12-month low of $181.36 and a 12-month high of $308.15. The company has a fifty day moving average of $234.36 and a two-hundred day moving average of $220.93. The company has a market cap of $9.84 billion, a price-to-earnings ratio of 20.37, a PEG ratio of 1.43 and a beta of 1.36. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.32 and a quick ratio of 1.08.

Charles River Laboratories International (NYSE:CRL – Get Rating) last issued its quarterly earnings results on Wednesday, February 22nd. The medical research company reported $2.98 EPS for the quarter, topping analysts’ consensus estimates of $2.75 by $0.23. Charles River Laboratories International had a return on equity of 20.98% and a net margin of 12.23%. The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the prior year, the business posted $2.49 earnings per share. The business’s quarterly revenue was up 21.5% on a year-over-year basis. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.25 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster sold 20,000 shares of the stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $250.00, for a total value of $5,000,000.00. Following the completion of the sale, the chief executive officer now directly owns 216,594 shares of the company’s stock, valued at $54,148,500. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO James C. Foster sold 20,000 shares of the company’s stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $250.00, for a total value of $5,000,000.00. Following the completion of the transaction, the chief executive officer now owns 216,594 shares of the company’s stock, valued at approximately $54,148,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Birgit Girshick sold 3,205 shares of the firm’s stock in a transaction dated Thursday, February 16th. The shares were sold at an average price of $254.39, for a total value of $815,319.95. Following the sale, the chief operating officer now directly owns 41,038 shares in the company, valued at $10,439,656.82. The disclosure for this sale can be found here. Insiders have sold 27,763 shares of company stock valued at $6,974,921 over the last 90 days. 1.10% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

(Get Rating)

Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.